#PSMA617 - Twitter Hashtag

over 1 year ago

#FDAApproval #ProstateCancer #177LuPSMA617 #Pluvicto #CancerTreatment #ProstateCancerTreatment #OncologyResearch #MSKResearch #PSMA617 #CancerInnovation #ProstateCancerAwareness #TargetedTherapy #CancerCare #NewCancerTreatment #TheMSKWay

Memorial Sloan Kettering Cancer Center

@MSKCancerCenter

over 1 year ago

The @US_FDA has expanded approval for 177Lu-PSMA-617 (Pluvicto), a treatment for patients with #prostatecancer, based on results from a phase 3 trial led by researchers at MSK. More patients can now benefit from the treatment. “This type of precision medicine is a game changer for people whose prostate cancer has spread outside of the prostate despite treatment with hormonal therapy,” says Dr. Michael Morris, a medical oncologist at MSK who led the phase 3 trial. Learn more: https://t.co/N12IxDxwhQ

MSKCancerCenter's tweet photo. The @US_FDA has expanded approval for 177Lu-PSMA-617 (Pluvicto), a treatment for patients with #prostatecancer, based on results from a phase 3 trial led by researchers at MSK. More patients can now benefit from the treatment.

“This type of precision medicine is a game changer for people whose prostate cancer has spread outside of the prostate despite treatment with hormonal therapy,” says Dr. Michael Morris, a medical oncologist at MSK who led the phase 3 trial. Learn more: https://t.co/N12IxDxwhQ

0

36

9

3

5K

0

3

0

192

Ashwin Singh Parihar, MBBS, MD

@TheNUCguy

over 4 years ago

Was just finishing a manuscript and now need to make a much welcome edit! 177Lu-PSMA-617 radioligand therapy gets FDA approved. Congratulations to all the people who made it possible! #Pluvicto @US_FDA #PSMA617 @DrAIravani @SNM_MI @MIRimaging

TheNUCguy's tweet photo. Was just finishing a manuscript and now need to make a much welcome edit!
177Lu-PSMA-617 radioligand therapy gets FDA approved. Congratulations to all the people who made it possible!
#Pluvicto @US_FDA #PSMA617 @DrAIravani @SNM_MI @MIRimaging https://t.co/bISY60tXHK

0

17

1

0

ICUrology @icurology

almost 5 years ago

Open Access🔓https://t.co/DiyA8fYwKg Our results identify improved PSA response to Lu-PSMA RLT in men with only LNM, especially in the chemotherapy naïve cohort, compared to previous series with more advanced mCRPC. #Lutetium177 #Lymphatic_metastasis #Prostate_cancer #PSMA617